Back

easier: interpretable predictions of antitumor immune response from bulk RNA-seq data

Lapuente-Santana, O.; Marini, F.; Ustjanzew, A.; Finotello, F.; Eduati, F.

2021-11-27 systems biology
10.1101/2021.11.26.470099 bioRxiv
Show abstract

Immunotherapy with immune checkpoint blockers (ICB) is associated with striking clinical success, but only in a small fraction of patients. Thus, we need computational biomarker-based methods that can anticipate which patients will respond to treatment. Current established biomarkers are imperfect due to their incomplete view of the tumor and its microenvironment. We have recently presented a novel approach that integrates transcriptomics data with biological knowledge to study tumors at a more holistic level. Validated in four different solid cancers, our approach outperformed the state-of-the-art methods to predict response to ICB. Here, we introduce estimate systems immune response (easier), an R/Bioconductor package that applies our approach to quantify biomarkers and assess patients likelihood to respond to immunotherapy, providing just the patients baseline bulk-tumor RNA-sequencing (RNA-seq) data as input.

Matching journals

The top 1 journal accounts for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.